Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer.

Szczegóły
Abstrakt

Tytuł:: Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer.
Autorzy:: Wen Z; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Feng Y; Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Hu Y; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Lian L; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Huang H; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Guo L; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Chen S; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yang Q; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Zhang M; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Wan L; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xu K; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Degejirifu; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yan X; Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, China.
Źródło:: Aging [Aging (Albany NY)] 2021 Jan 13; Vol. 13 (2), pp. 1872-1882. Date of Electronic Publication: 2021 Jan 13.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Albany, NY : Impact Journals, LLC
MeSH Terms:: Drug Delivery Systems*
Nanotubes, Carbon*
Antineoplastic Agents/*therapeutic use
ErbB Receptors/*genetics
Liver Neoplasms/*drug therapy
RNA, Small Interfering/*therapeutic use
Sorafenib/*therapeutic use
Animals ; Antineoplastic Agents/administration & dosage ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; ErbB Receptors/metabolism ; Hep G2 Cells ; Humans ; Liver/drug effects ; Liver/metabolism ; Liver Neoplasms/genetics ; Mice ; Mice, Nude ; Neoplasm Transplantation ; RNA, Small Interfering/administration & dosage ; Sorafenib/administration & dosage
References:: Semin Intervent Radiol. 2017 Jun;34(2):145-166. (PMID: 28579683)
World J Clin Oncol. 2016 Aug 10;7(4):331-6. (PMID: 27579253)
Br J Cancer. 2015 Mar 17;112(6):957-62. (PMID: 25742467)
Liver Cancer. 2018 Sep;7(3):235-260. (PMID: 30319983)
J Cell Sci. 2009 Feb 15;122(Pt 4):437-41. (PMID: 19193868)
Cancers (Basel). 2017 May 17;9(5):. (PMID: 28513565)
Cancer Lett. 2018 Jan 1;412:283-288. (PMID: 29050983)
J Vasc Interv Radiol. 2018 Aug;29(8):1061-1067. (PMID: 29934260)
Contemp Oncol (Pozn). 2018;22(3):165-171. (PMID: 30455588)
Lung Cancer. 2017 Nov;113:79-84. (PMID: 29110854)
Indian J Cancer. 2015 Jul-Sep;52(3):262-4. (PMID: 26905103)
Nat Rev Drug Discov. 2006 Oct;5(10):835-44. (PMID: 17016424)
Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63. (PMID: 24355989)
Minerva Endocrinol. 2017 Mar;42(1):64-76. (PMID: 26112458)
Mol Ther Nucleic Acids. 2018 Mar 2;10:317-330. (PMID: 29499944)
Oncol Rep. 2013 Jan;29(1):260-8. (PMID: 23117577)
Gene. 2006 Jan 17;366(1):2-16. (PMID: 16377102)
ACS Appl Mater Interfaces. 2020 Apr 15;12(15):17193-17206. (PMID: 32207914)
Expert Opin Investig Drugs. 2017 Apr;26(4):463-479. (PMID: 28271910)
Pharm Res. 2012 Apr;29(4):1007-19. (PMID: 22169985)
Life Sci. 2019 Dec 15;239:117013. (PMID: 31678287)
Chin J Cancer Res. 2018 Dec;30(6):571-579. (PMID: 30700925)
Sci Rep. 2017 Mar 31;7:45846. (PMID: 28361988)
Ann Oncol. 2018 May 1;29(5):1108-1119. (PMID: 29659677)
Contributed Indexing:: Keywords: epidermal growth factor receptor; liver cancer; multiwalled carbon nanotubes; sorafenib
Substance Nomenclature:: 0 (Antineoplastic Agents)
0 (Nanotubes, Carbon)
0 (RNA, Small Interfering)
9ZOQ3TZI87 (Sorafenib)
EC 2.7.10.1 (ErbB Receptors)
Entry Date(s):: Date Created: 20210113 Date Completed: 20210510 Latest Revision: 20210510
Update Code:: 20240105
PubMed Central ID:: PMC7880368
DOI:: 10.18632/aging.103905
PMID:: 33440348
: Czasopismo naukowe

Objective: This study aimed to investigate the effects of multiwalled carbon nanotubes (MWNTs) co-delivering sorafenib (Sor) and epidermal growth factor receptor (EGFR) siRNA (MWNT/Sor/siRNA) on tumor growth in liver cancer (LC).
Results: MWNT/Sor/siRNA was proved to possess increased Sor release, high siRNA stability, and enhanced cellular uptake. In addition, MWNT treatment has few effects on cell proliferation and apoptosis in HepG2 cells; however, MWNT/Sor/siRNA treatment significantly inhibited clone number and induced cell apoptosis, which shows a more favorable antitumor effect than MWNT/Sor and free Sor and free siRNA in HepG2 cells. Moreover MWNT/Sor/siRNA treatment has the most significant antitumor effect in vivo .
Conclusions: MWNT/Sor/siRNA exhibited a superior antitumor effect in vitro and in vivo .
Methods: The MWNT/Sor and MWNT/Sor/siRNA were prepared, and then the morphologies of MWNT/Sor/siRNA were analyzed. In vitro Sor release assay, siRNA stability and cellular uptake of MWNT/Sor/siRNA were performed as well. Next, the effects of MWNT, free Sor, free siRNA, MWNT/Sor and MWNT/Sor/siRNA were evaluated by colony-forming assay, and cell apoptosis assay in HepG2 cells. Meanwhile, the level of EGFR and proteins associated with apoptosis was tested. Furthermore, the anti-tumor effects of MWNT/Sor/siRNA on LC xenograft mice were also unraveled.

Informacja